US EditionVittoria Biotherapeutics to Present VIPER-101 Phase 1 Trial at 2025 ASCO Annual Meeting
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Vittoria Biotherapeutics to Present VIPER-101 Phase 1 Trial at 2025 ASCO Annual Meeting
PHILADELPHIA, PA — Vittoria Biotherapeutics Inc. has announced its upcoming presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The trials-in-progress poster will spotlight the design and goals of the ongoing Phase 1 study of VIPER-101, the company’s lead investigational CD5-targeted CAR-T therapy for relapsed or refractory T-cell lymphoma. The presentation will take place on Sunday, June 1,…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
